2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|November 20, 2019
Low-Impurity Sucrose Lowers Risk of Protein Instability in Biopharmaceutical Formulation
Author(s)Pharmaceutical Technology Editors
A new sucrose product from MilliporeSigma has reduced nanoparticle impurities.
MilliporeSigma developed a new filtration-based manufacturing process resulting in a new, highly purified sucrose grade with reduced levels of nanoparticle impurities (NPI). The new product, Sucrose EMPROVE EXPERT Ph Eur, ChP, JP, NF, is useful for biopharmaceutical formulation as a protein-stabilizing excipient. The product is part of the company’s Emprove Program, which facilitates drug product manufacturers’ risk assessment workflows and supplier qualification.
MilliporeSigma designed the new purification process and associated nanoparticle analytics of sucrose in a collaboration with Coriolis Pharma. Compared to non-purified sucrose, the new product offers a low level of NPIs on the limit of detection of current technologies, reducing risk of protein stability; less interference with analytical methods; high batch-to-batch consistency; and a reduced risk of API damage.
Source: MilliporeSigma
Related to this article
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.